Literature DB >> 1373118

Transformation by FosB requires a trans-activation domain missing in FosB2 that can be substituted by heterologous activation domains.

R Wisdom1, J Yen, D Rashid, I M Verma.   

Abstract

Two functionally distinct proteins derived from the FosB gene by alternative splicing have recently been described. FosB protein transforms fibroblasts efficiently, whereas FosB2 protein, a carboxy-terminally truncated form of FosB, does not, despite the fact that both proteins can participate in high-affinity, sequence-specific DNA binding as part of a heterodimeric complex with c-Jun protein. We show here that the functional difference between these proteins is the result of the presence of a potent proline-rich transcriptional activation domain in the carboxy-terminal amino acids unique to FosB. This conclusion is supported by three lines of evidence: (1) Mutations in the carboxy-terminal region of FosB that impair transcriptional activation also reduce transforming potential, despite the fact that DNA binding as part of a complex with c-Jun is not affected; (2) the carboxy-terminal region unique to FosB functions as an activation domain when fused to the DNA-binding domain of GAL4; and (3) transforming potential can be conferred on FosB2 by fusing any of several different well-characterized trans-activation domains. These results identify an additional functional requirement for transformation by Fos proteins and have implications for the mechanism(s) of mitogenic signaling by the AP-1 transcription complex.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373118     DOI: 10.1101/gad.6.4.667

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  20 in total

1.  Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product.

Authors:  D Vallone; S Battista; G M Pierantoni; M Fedele; L Casalino; M Santoro; G Viglietto; A Fusco; P Verde
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

2.  Absence of a persistently elevated 37 kDa fos-related antigen and AP-1-like DNA-binding activity in the brains of kainic acid-treated fosB null mice.

Authors:  A Mandelzys; M A Gruda; R Bravo; J I Morgan
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

3.  Proto-oncogene FosB: the amino terminus encodes a regulatory function required for transformation.

Authors:  R Wisdom; I M Verma
Journal:  Mol Cell Biol       Date:  1993-05       Impact factor: 4.272

4.  The bZIP domains of Fos and Jun mediate a physical association with the TATA box-binding protein.

Authors:  L J Ransone; L D Kerr; M J Schmitt; P Wamsley; I M Verma
Journal:  Gene Expr       Date:  1993

5.  Proliferative activation of quiescent Rat-1A cells by delta FosB.

Authors:  Y Nakabeppu; S Oda; M Sekiguchi
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

6.  Inhibiting activator protein-1 activity alters cocaine-induced gene expression and potentiates sensitization.

Authors:  R F Paletzki; M V Myakishev; O Polesskaya; A Orosz; S E Hyman; C Vinson
Journal:  Neuroscience       Date:  2008-02-07       Impact factor: 3.590

7.  Retroviral insertions downstream of the heterogeneous nuclear ribonucleoprotein A1 gene in erythroleukemia cells: evidence that A1 is not essential for cell growth.

Authors:  Y Ben-David; M R Bani; B Chabot; A De Koven; A Bernstein
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

8.  c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms.

Authors:  R Wisdom; R S Johnson; C Moore
Journal:  EMBO J       Date:  1999-01-04       Impact factor: 11.598

9.  Transformation by Fos proteins requires a C-terminal transactivation domain.

Authors:  R Wisdon; I M Verma
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

10.  Synergistic activation of human involucrin gene expression by Fra-1 and p300--evidence for the presence of a multiprotein complex.

Authors:  James F Crish; Richard L Eckert
Journal:  J Invest Dermatol       Date:  2007-09-20       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.